Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:35pm, Monday, 02'nd Aug 2021
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
04:30pm, Monday, 02'nd Aug 2021
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290%
03:03pm, Thursday, 24'th Jun 2021
Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
Why Paratek Pharmaceuticals Stock Is Sinking Today
12:29pm, Wednesday, 16'th Jun 2021
The company reduced its 2021 revenue outlook.
-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment
Why Paratek Pharmaceuticals Crushed the Market Today
06:36pm, Tuesday, 01'st Jun 2021
The company gets off to a roaring start in June with an important FDA nod.
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Jun 2021
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek's Stock Gains After Nuzyra's Oral Regime Wins FDA Approval For Pneumonia
09:38am, Tuesday, 01'st Jun 2021
The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP). The
- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion
Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
04:17pm, Wednesday, 26'th May 2021
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2021 Results - Earnings Call Transcript
02:52pm, Monday, 17'th May 2021
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2021 Results - Earnings Call Transcript
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates
09:47am, Monday, 17'th May 2021
Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals: Q1 Earnings Insights
07:47am, Monday, 17'th May 2021
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 40.91% year over year to ($0.39), which missed the
Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement
07:30am, Monday, 17'th May 2021
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
03:52pm, Tuesday, 27'th Apr 2021
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
